Y-27632 dihydrochloride: Selective ROCK Inhibitor for Rho/ROCK Pathway Studies

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC₅₀ values near 140 nM for ROCK1 and Ki of 300 nM for ROCK2. The compound shows >200-fold selectivity over related kinases, minimizing off-target effects (De Hoyos et al., 2023). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression, supporting applications in cytoskeletal, stem cell, and cancer research (APExBIO, A3008). Y-27632’s solubility profile (≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water) and stability under standard conditions enable consistent experimental reproducibility. APExBIO’s formulation is widely referenced for cell viability and tumor invasion assays.

Biological Rationale

The Rho/ROCK signaling pathway regulates actin cytoskeleton dynamics, cell shape, motility, and proliferation. Rho-associated kinases (ROCK1 and ROCK2) phosphorylate downstream targets, controlling stress fiber and focal adhesion formation. Dysregulation of this pathway is linked to cancer progression, metastasis, and abnormal cell cycle control (De Hoyos et al., 2023). Selective inhibition of ROCK kinases is essential for dissecting their roles in cellular processes and disease models. Y-27632 dihydrochloride provides a highly specific chemical tool for pathway modulation, minimizing confounding effects from unrelated kinases (APExBIO).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively inhibits the ATP-binding site of ROCK1 (IC₅₀: 140 nM) and ROCK2 (Ki: 300 nM), preventing phosphorylation of substrates such as myosin light chain (MLC) and LIM kinase. This inhibition disrupts actin stress fiber assembly, reduces focal adhesion formation, and impairs cytokinesis by blocking contractile ring formation (De Hoyos et al., 2023). The selectivity of Y-27632 exceeds 200-fold versus kinases like PKC, MLCK, and PAK, ensuring targeted modulation of the Rho/ROCK axis.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM, and ROCK2 with a Ki of 300 nM, ensuring high potency and selectivity (De Hoyos et al., 2023, Table 1).
• It achieves >200-fold selectivity over PKC, PKA, MLCK, and PAK at concentrations relevant for cell-based assays (APExBIO).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (1–10 μM, 37°C, standard culture media) (De Hoyos et al., 2023).
• In vivo, it suppresses tumor invasion and metastasis in mouse models by targeting ROCK-dependent processes (De Hoyos et al., 2023).
• Y-27632 enhances survival and viability of pluripotent stem cells by preventing dissociation-induced apoptosis, supporting regenerative medicine protocols (Related Internal).

This article updates and extends EGFP-Sarna (A3008 Q&A) by providing new quantitative selectivity data and clarifying in vivo anti-tumoral benchmarks. For advanced protocols and troubleshooting, see VX-661.com, while the detailed comparison to alternative cytoskeletal modulators in G-418 Sulfate is complemented here by updated selectivity metrics and real-world storage guidance.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is validated for:

• Studying actin cytoskeleton dynamics and Rho/ROCK signaling in mammalian cells.
• Enhancing human pluripotent stem cell survival during single-cell passaging.
• Modulating smooth muscle cell contraction and proliferation in vitro.
• Suppressing tumor cell invasion and metastasis in animal models.
• Facilitating cytokinesis studies and cell cycle progression assays.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit unrelated kinases such as Src, PI3K, or MAPK at experimental concentrations; using it for off-pathway targets is not supported.
• Long-term storage of prepared aqueous or organic solutions (>1 month) at 4°C is discouraged due to potential degradation; use freshly prepared aliquots (APExBIO).
• Y-27632 may not reverse established cytoskeletal structures in terminally differentiated tissues; effects are most robust in proliferative or actively remodeling cells.
• Not suitable as a general anti-proliferative agent outside ROCK-dependent pathways; efficacy is context-dependent.
• Solubility in water, DMSO, and ethanol is high, but incomplete dissolution at low temperature or without agitation may yield inconsistent concentrations.

Workflow Integration & Parameters

Y-27632 dihydrochloride (SKU A3008) supplied by APExBIO is formulated as a solid, stable when stored desiccated at ≤4°C. For stock solutions, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Enhance solubilization by warming to 37°C or using an ultrasonic bath. Store stock solutions at <–20°C for up to several months; avoid repeated freeze-thaw cycles. Typical working concentrations in cell culture range from 1–10 μM. In microfluidic co-culture devices, Y-27632 can be used to modulate epithelial and neuronal interactions by controlling cytoskeletal contractility (De Hoyos et al., 2023). For detailed protocols and troubleshooting, see 2xPowderBlend for guidance on assay design, storage, and concentration selection.

Conclusion & Outlook

Y-27632 dihydrochloride remains the gold-standard selective ROCK inhibitor for research in cytoskeletal organization, stem cell viability, and tumor biology. Its high potency, robust solubility, and specificity facilitate reproducible, high-sensitivity Rho/ROCK pathway studies. APExBIO’s A3008 variant offers reliable performance for diverse biomedical workflows. Ongoing innovations in microfluidic and organoid models are expanding the applications of Y-27632, enabling precise dissection of neuro-epithelial and tumor microenvironment interactions (De Hoyos et al., 2023).